Ryvu Therapeutics Reports 2024 Fiscal Year Financials
Read More
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
Read More
Ryvu Therapeutics awarded two grants to support next-generation ADCs development
Read More
